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The introduction of the immunomodulatory drug lenalidomide has significantly improved response rates and survival in patients with multiple myeloma (MM). 1, 2 Recently, two studies by the French IFM and the US CALGB groups have investigated maintenance lenalidomide after autologous stem cell transplantation (ASCT), and demonstrated significant improvement in the progression-free survival (PFS) with significant overall survival benefit reported by the CALGB study. 3, 4 Likewise, a randomized study by the Italian Myeloma Network demonstrated a significant prolongation of PFS in elderly patients not eligible for ASCT who received lenalidomide maintenance. 5 On the basis of these studies, maintenance lenalidomide has been widely adopted in the myeloma community.
Lenalidomide exerts its effects through a multitude of complex mechanisms of action. Extensive investigations have revealed that it has direct anti-tumor activity by targeting cellular cytoskeletal organization, cell cycle, inhibition of oncogenes, induction of tumor suppressor genes, activation of apoptotic pathways and inhibition of angiogenesis, and it also exerts complex immunomodulatory effects on the tumor microenvironment. 6, 7 These mechanisms lead to various biological phenotypes, some of which have not yet been fully elucidated.
We have previously reported a small series of six patients receiving prolonged lenalidomide treatment and who presented with a polyclonal immunoglobulin A (IgA) gammopathy characterized by a marked elevation of the serum IgA level and polyclonal plasmacytosis in the bone marrow, which was associated with good control of the disease. 8 Given the potential important clinical implications of this observation, we undertook a retrospective analysis of all patients treated at Memorial SloanKettering Cancer Center (MSKCC) with a prolonged course of lenalidomide and here describe a prevalent, yet previously undescribed, protective immune deregulation. We further characterize its clinical features, and prognostic significance.
The primary objective of the study was to determine the incidence of this polyclonal immune activation with Ig levels exceeding the normal range in patients with MM treated with maintenance lenalidomide. Secondary objectives were to further define the clinical characteristics of patients exhibiting polyclonal immune activation and to analyze the association with PFS. This study was approved by the Institutional Review Board.
The study population consisted of all patients with MM who received a prolonged course of lenalidomide (46 months) at MSKCC between 2006 and 2011, either as maintenance therapy after ASCT or continuous treatment after initial induction therapy (n ¼ 104). Data on baseline and treatment characteristics, response and relapse and progression of disease (R/POD) were collected from a database of all the MM patients treated at MSKCC. Immunohistochemistry (IHC) assessment of bone marrow plasmacytosis, and Ig and light chain expression were performed on paraffin-embedded tissue sections from bone marrow biopsies stained separately using antibodies against kappa and lambda (Clones L1C1 and Lamb14, respectively, Cell Marque, Rocklin, CA, USA); CD138 (clone MI15, DAKO, Carpinteria, CA, USA); IgG and IgA (polyclonal rabbit antibody, Ventana, Tucson, AZ, USA).
For the analysis of prognostic significance, the change in levels of IgA (for patients with IgG MM), IgG (for patients with IgA MM) or both (for patients with free-light chain (FLC) MM) over the first 6 months of lenalidomide therapy was calculated. The median absolute change in IgA or IgG levels was used to dichotomize patients into those above and below the median. Using 6 months after lenalidomide initiation as a landmark, PFS for patients above and below the median Ig elevation was estimated using KaplanMeier methodology. The survival distributions for the two groups were compared using a logrank test. In addition, Cox proportional hazards regression investigated the association between time to progression or death and Ig elevation above or below the median, adjusting for age, International Staging System (ISS) and cytogenetic risk. A total of 25 patients were dropped from this analysis owing to unknown ISS or cytogenetic risk. Significance was defined as Po0.05 based on a two-sided test. Statistical analyses were conducted using R statistical software.
Data on baseline and treatment characteristics, response status and R/POD were collected from a database of all the MM patients treated at MSKCC. One hundred and four patients who had received over 6 months of lenalidomide were included in the study. The median estimated follow up was 22.6 months (15.2-33.2). Median age was 60 with 59% of male gender. Cytogenetic analysis by karyotyping and Fluorescence in situ hybridization revealed that 66 patients (63%) had standard risk, whereas 25 (24%) had high risk, with 13 (13%) missing data. By ISS, 41 patients (39%) had stage I, 33 (32%) stage II and 19 (18%) stage III with 11 (11%) missing data. Seventy-five patients (72%) received lenalidomide post ASCT, whereas 29 (28%) received it without a transplant as part of continuous treatment.
Among the study population, 21 patients (20%) were noted to have a polyclonal gammopathy with Ig elevation exceeding the upper limit of normal (ULN) range while receiving lenalidomide therapy. This polyclonal gammopathy could be unambiguously distinguished from the underlying monoclonal gammopathy because it involved a different isotype (n ¼ 15), and/or because no monoclonal gammopathy could be detected by immunofixation (figure 1a). The polyclonal gammopathy affected the IgA isotype in 13 patients, IgG in 6 and both IgA and IgG in 2. All 21 patients were without evidence of R/POD by serologic or clinical criteria at the time of polyclonal Ig elevation. The median time from the initiation of lenalidomide to polyclonal elevation of Ig above the ULN range was 10.9 months (range 2 to 38.6 months), with the median peak IgA level of 587 mg/dl (range 404 to 1190 mg/dl), and the median peak IgG level of 1800 mg/dl (range 1575 to 2650 mg/dl). Out of 21 patients, 19 achieved normalization of FLC ratios before polyclonal Ig elevation with, in some patients, rise in both FLC to above normal range.
Bone marrow aspirates and biopsies were available in 12 patients during the period of Ig elevation, and the median bone marrow plasmacytosis was 12% (range 5 to 20%) based on aspirate counts. IHC on paraffin-embedded tissue sections from the bone marrow biopsies demonstrated mild to moderate increase in CD138 þ cells, at levels similar to the aspirate, Accepted article preview online 23 April 2013; advance online publication, 17 May 2013 distributed in small aggregates and displaying no light chain restriction. IHC using IgA and IgG antibody staining in the patients with IgA elevation confirmed that most plasma cells were IgA producing and were not consistent with the original IgG-producing myeloma clones (Figure 1b) .
Among the 21 patients, 1 discontinued therapy secondary to side effects with subsequent resolution of polyclonal gammopathy, while 3 patients discontinued lenalidomide secondary to R/POD, which was preceded by reversal of the polyclonal gammopathy. The remaining 17 patients continue to receive lenalidomide therapy to date (median 32.9 months, range 12 to 52.3 months) with no evidence of serologic or clinical R/POD and 15 among them have persistent polyclonal gammopathy.
Given the perceived prolonged benefit of lenalidomide in patients with abnormal polyclonal Ig elevation, we hypothesized that increase in polyclonal Ig levels may be associated with a better outcome. To investigate the potential prognostic significance of this polyclonal immune response on PFS, we performed a landmark analysis on all 104 patients based on the magnitude of the absolute Ig increase between baseline level before the initiation of lenalidomide and at 6 months after starting therapy. The patients were divided into 2 groups based on the median absolute elevation in the levels of IgA (34 mg/dl) and/or IgG (171 mg/dl). As shown in Figure 2 , patients with Ig elevation above the median levels appeared to have prolonged PFS (logrank P-value: 0.01) with 2 year PFS of 80 and 47% for patients above and below the median Ig levels, respectively. Adjusting for age, ISS and cytogenetics, the decreased risk of progression or death among patients with Ig elevation above the median remained significant (HR: 0.25 (0.08-0.78), P-value: 0.02).
In summary, polyclonal Ig (with sometimes FLC) elevation exceeding the ULN associated with striking polyclonal plasmacytosis occurs with a relatively high frequency (20%) in patients with MM treated with extended courses of lenalidomide, and reflects an underlying more prevalent polyclonal immune activation associated with prolonged lenalidomide treatment. While the underlying mechanism of this immunologic phenomenon remains under investigation, we find that its occurrence is associated with extended PFS, and has further implications for the prognostic value of absolute Ig recovery in all the patients on treatment. Most importantly, awareness of this effect is crucial especially in view of the associated significant-and often striking bone marrow plasmacytosis, which may mistakenly be construed as R/POD in patients whose disease is actually well controlled. These observations highlight the controversial issue regarding the significance and interpretation of marrow examination in the setting of response evaluation after treatment in patients with MM. The current definition of complete response in MM as established by the International Myeloma Working Group (IMWG) criteria includes a requirement for a bone marrow examination, showing less than 5% plasma cells in addition to negative serum and urine immunofixation. 9 Furthermore, Chee et al. 10 have recently stressed the clinical importance of performing a bone marrow biopsy for CR confirmation and the prognostic significance of bone marrow plasmacytosis exceeding 5%. Our findings raise an important cautionary warning when interpreting marrow plasmacytosis in patients who are treated with lenalidomide, especially in the context of maintenance therapy, as many of these patients may have a beneficial reactive polyclonal plasmacytosis that must not be confused with disease recurrence. 
